This pooled analysis using data from 1253, 835, and 143 pancreatic IPMN patients revealed that overall KRAS, GNAS, and RNF43 mutations were detected in 61, 56, and 23 %, respectively. This evidence concerns the gene GNAS and pancreatic intraductal papillary-mucinous neoplasm.